Neurocrine Biosciences (NBIX) Net Equity Issued and Repurchased (2010 - 2026)
Neurocrine Biosciences (NBIX) reported Net Equity Issued and Repurchased of -$66.8 million for Q3 2026, compared with $45.6 million a year earlier.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Net Equity Issued and Repurchased (2010 - 2026) Analysis & Trends
Over the twelve months ended Sep 30, 2026, Neurocrine Biosciences' Net Equity Issued and Repurchased came in at $12.9 million; for FY2025, it was -$38.3 million.
- By year, Net Equity Issued and Repurchased came in at -$177.9 million in FY2024, $65.3 million in FY2023 (+46.1%), $44.7 million in FY2022 (+62.5%) and $27.5 million in FY2021 (-5.5%).
- The Q3 2026 figure ranks as the lowest quarterly Net Equity Issued and Repurchased since Q1 2025.
- The high point for year-over-year Net Equity Issued and Repurchased in five years was Q1 2024 (growth of 752.4%); the low point was Q1 2022 (a decline of 59.9%).
- Per Business Quant data, the three quarters before Q3 2026 came in at $72.8 million (Q2 2026), -$30.4 million (Q1 2026) and $37.3 million (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | -377.00 Mn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | -966.00 Mn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | -5.00 Mn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | -406.00 Mn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 4.00 Mn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | - |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | -283.00 Mn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | - |
| 10 | Neurocrine Biosciences | 17.13 Bn | 13.21 Bn | 1.10 Bn | -66.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | -66.80 Mn |
| Jun 30, 2026 | 72.80 Mn |
| Mar 31, 2026 | -30.40 Mn |
| Dec 31, 2025 | 37.30 Mn |
| Sep 30, 2025 | 45.60 Mn |
| Jun 30, 2025 | -3.30 Mn |
| Mar 31, 2025 | -117.90 Mn |
| Dec 31, 2024 | -290.00 Mn |
| Sep 30, 2024 | 26.40 Mn |
| Jun 30, 2024 | 15.80 Mn |
| Mar 31, 2024 | 69.90 Mn |
| Dec 31, 2023 | 35.40 Mn |
| Sep 30, 2023 | 18.80 Mn |
| Jun 30, 2023 | 2.90 Mn |
| Mar 31, 2023 | 8.20 Mn |
| Dec 31, 2022 | 24.60 Mn |
| Sep 30, 2022 | 11.40 Mn |
| Jun 30, 2022 | 2.60 Mn |
| Mar 31, 2022 | 6.10 Mn |
| Dec 31, 2021 | 1.80 Mn |
API Access
Neurocrine Biosciences Net Equity Issued and Repurchased API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-equity-issued-and-repurchased&ticker=NBIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-equity-issued-and-repurchased", "ticker": "NBIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-equity-issued-and-repurchased&ticker=NBIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();